AcuityMD Raises $80 Million in Series C Funding
AcuityMD, a Boston-based company specializing in MedTech intelligence, announced on April 21, 2026, that it has secured $80 million in a Series C funding round. The round was led by StepStone Group, with participation from Benchmark, Iconiq, Redpoint Ventures, and Atreides Management.
Company Overview
AcuityMD is known for its platform that integrates precise data with AI-powered insights and intuitive workflows. This combination helps medical technology teams accelerate their operations and achieve more significant results. The company aims to streamline the workflow for MedTech professionals by providing them with actionable intelligence.
Key Executives
The company was co-founded by Michael Monovoukas, who serves as CEO, alongside Lee Smith, the Head of Commercial Development, and Robert Coe, the Chief Technology Officer. Their combined expertise drives the innovation and growth of AcuityMD in the MedTech space.
Investor Details
The Series C funding round was prominently led by StepStone Group. Other notable investors include Benchmark, Iconiq, Redpoint Ventures, and Atreides Management. This diverse group of investors highlights the confidence in AcuityMD's vision and potential to impact the MedTech industry.
Use of Funds
While specific plans for the newly raised funds were not detailed, it is expected that AcuityMD will use the capital to further develop their platform and expand their market presence. This could involve enhancing their AI capabilities, expanding their team, or entering new geographical markets.
Conclusion
With this significant investment, AcuityMD is well-positioned to continue its growth trajectory and further refine its offerings in the MedTech sector. The backing from prominent investors underscores the potential seen in AcuityMD's approach to revolutionizing medical technology intelligence.